Login to Your Account



Zai nabs China rights for Tesaro's PARP inhibitor in ovarian cancer

By Shannon Ellis
Staff Writer

Monday, October 3, 2016

SHANGHAI – It's not often that Chinese biopharmas are able to nab China rights for a promising late-stage oncology candidate in global trials. But that's exactly what Shanghai-based Zai Labs Ltd. did.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription